Semaglutide is the active ingredient in Wegovy, but they are not interchangeable terms. Semaglutide is the drug compound itself, while Wegovy is one specific brand name product built around that compound. Think of it like ibuprofen and Advil: same molecule, different packaging, dosing, and approved uses. Other brand names also contain semaglutide, most notably Ozempic, which is approved for type 2 diabetes rather than weight management.
What Semaglutide Actually Is
Semaglutide belongs to a class of drugs that mimic a natural gut hormone called GLP-1. When you eat, your body releases this hormone to signal fullness, slow digestion, and trigger insulin release. Semaglutide copies that process but lasts much longer than the natural version, which is why it only needs to be taken once a week. The result is reduced appetite, slower stomach emptying, and lower blood sugar levels.
Several products use semaglutide as their active ingredient, each tailored to a different medical purpose. Wegovy is formulated and dosed specifically for weight loss and cardiovascular risk reduction. Ozempic uses the same molecule but at a lower maximum dose and is FDA-approved for managing type 2 diabetes. There is also an oral tablet form of semaglutide sold under the brand name Rybelsus for diabetes.
How Wegovy Differs From Ozempic
The biggest practical difference is dosing. Wegovy’s maximum maintenance dose is 2.4 mg per week, while Ozempic tops out at 2 mg. That higher ceiling matters because the weight loss effects of semaglutide are dose-dependent: more of the drug generally produces more appetite suppression and greater weight reduction. Both are injected under the skin once a week using a prefilled pen, and both share the same side effect profile since the underlying molecule is identical.
The other major difference is what each product is approved to treat. Ozempic’s label covers blood sugar control in type 2 diabetes. Wegovy’s label is broader in the weight management space, covering adults with obesity (BMI of 30 or higher), adults with overweight (BMI of 27 to 29.9) who also have at least one weight-related health condition, and even adolescents aged 12 and older with obesity. Some doctors prescribe Ozempic off-label for weight loss, but only Wegovy carries that official FDA indication.
Wegovy’s FDA-Approved Uses
Wegovy started as a weight management drug, but its approved uses have expanded significantly. In March 2024, the FDA approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have established heart disease along with obesity or overweight. That approval was based on a large trial of over 17,600 participants. Major cardiovascular events occurred in 6.5% of people taking Wegovy compared to 8% of those on placebo, a meaningful reduction.
The full list of current FDA indications for the injectable form includes:
- Cardiovascular risk reduction in adults with heart disease and obesity or overweight
- Long-term weight management in adults and adolescents 12 and older with obesity, or adults with overweight plus a related health condition
- Liver disease treatment for a specific type of fatty liver disease with moderate to advanced scarring (formerly called NASH, now called MASH)
All of these indications specify that Wegovy should be used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment.
The Dose Escalation Schedule
You don’t start Wegovy at the full 2.4 mg dose. Instead, you follow a gradual 16-week ramp-up designed to let your body adjust and reduce the severity of side effects, particularly nausea. The schedule works in four-week blocks:
- Weeks 1 through 4: 0.25 mg once weekly
- Weeks 5 through 8: 0.5 mg once weekly
- Weeks 9 through 12: 1 mg once weekly
- Weeks 13 through 16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (maintenance dose)
Adults may stay at 1.7 mg for maintenance if the full 2.4 mg dose isn’t tolerated, though the higher dose is generally preferred for maximum benefit. For adolescents, the target is always 2.4 mg. Each dose comes in its own prefilled pen, so you’ll cycle through different pen strengths as you titrate up.
Common Side Effects
Because Wegovy and Ozempic contain the same molecule, they share nearly identical side effect profiles. The most frequently reported issues are gastrointestinal. Nausea is the hallmark complaint, especially during the early dose escalation weeks, and it tends to improve as your body adapts. Vomiting, diarrhea, and constipation are also common. Many people experience bloating, gas, heartburn, or a persistent feeling of stomach fullness.
The gradual dose increase exists specifically to soften these effects. Most people find that symptoms are worst in the first week or two after each dose bump and then settle down. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help manage discomfort during the transition periods. People who had significant GI issues on Ozempic will likely experience similar challenges on Wegovy since the drug itself is the same.
Why the Distinction Matters
Understanding that semaglutide is the drug and Wegovy is the product matters for a few practical reasons. Insurance coverage often depends on which brand is prescribed and for what condition. A plan might cover Ozempic for diabetes but deny Wegovy for weight loss, even though both contain semaglutide. If your doctor writes a prescription for one, your pharmacy cannot substitute the other, because they are separate FDA-approved products with different dosing, different pen devices, and different approved indications.
Compounding pharmacies have also entered the picture, offering custom-made semaglutide formulations at lower prices. These compounded versions contain the same active molecule but are not FDA-approved products, and their quality and consistency can vary. If you’re comparing options, knowing that “semaglutide” is the ingredient and “Wegovy” is one specific, FDA-regulated version of it helps you ask the right questions about what you’re actually getting.